Cited by 415Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, Elizabeth A., Atwal, Siminder, Liu, Weiqun, Raja, Rajiv, Fine, Bernard M., Hughes, Brett G.M., Hicks, Rodney J., Hampton, Garret M., Amler, Lukas C., Pirzkall, Andrea, Lackner, Mark R.·2012·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-11-3148

Published version of a preprint

Open this paper in CoChat — free account

Abstract

PURPOSE: Elevated levels or increases in circulating tumor cells (CTC) portend poor prognosis in patients with epithelial cancers. Less is known about CTCs as surrogate endpoints or their use for predictive biomarker evaluation. This study investigated the utility of CTC enumeration and characterization using the CellSearch platform, as well as mutation detection in circulating tumor DNA (ctDNA), in patients with advanced non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: Forty-one patients were enrolled in a single-arm phase II clinical trial of erlotinib and pertuzumab. Peripheral blood was analyzed for CTC enumeration, EGFR expression in CTCs, and detection of oncogenic mutations in CTCs and ctDNA. Changes in CTC levels were correlated with 2[18F]fluoro-2-deoxy-D-glucose-positron emission tomographic (FDG-PET) and computed tomographic (CT) imaging and survival endpoints. RESULTS: CTCs were detected (≥ 1 CTC) at baseline in 78% of patients. Greater sensitivity for mutation detection was observed in ctDNA than in CTCs and detected mutations were strongly concordant with mutation status in matched tumor. Higher baseline CTC counts were associated with response to treatment by Response Evaluation Criteria in Solid Tumors (RECIST, P = 0.009) and decreased CTC counts upon treatment were associated with FDG-PET and RECIST response (P = 0.014 and P = 0.019) and longer progression-free survival (P = 0.050). CONCLUSION: These data provide evidence of a correlation between decreases in CTC counts and radiographic response by either FDG-PET or RECIST in patients with advanced NSCLC. These findings require prospective validation but suggest a potential role for using CTC decreases as an early indication of response to therapy and ctDNA for real-time assessment of mutation status from blood.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-3148

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Bono, J. S. D., Scher, H. I., Montgomery, B., Parker, C. C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. M. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,189
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Cohen, S. J., Punt, C. J. A., Iannotti, N. O., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E. P., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,876
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453
Self-citation

Show all 29 references

Research works printed but not linked: 2

Ries, 2005, Cancer Statistics Review, 1975–2002
Hughes B, 2011, Combination of pertuzumab and erlotinib as 2nd/3rd-line treatment for patients with metastatic non-small cell lung cancer: safety and anti-tumour activity by FDG-PET/CT imaging changes, ECCO/ESMO European Multidisciplinary Congress; 23–27

Sorted by citations

Items 101–200 of 415

The potential of liquid biopsies
Buder, A., Tomuta, C., & Filipits, M. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000267 · Cited by 67
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.
Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66
Tannic Acid (TA)-Functionalized Magnetic Nanoparticles for EpCAM-Independent Circulating Tumor Cell (CTC) Isolation from Patients with Different Cancers
Ding, P., Wang, Z., Wu, Z., Hu, M., Zhu, W., Sun, N., & Pei, R. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c20916 · Cited by 66
The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer
Zhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 66
Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer
Shishido, S. N., Carlsson, A., Nieva, J., Bethel, K., Hicks, J. B., Bazhenova, L., & Kuhn, P. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2035-8 · Cited by 64
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
Crespo, M., van Dalum, G., Ferraldeschi, R., Zafeiriou, Z., Sideris, S., Lorente, D., Bianchini, D., Rodrigues, D. N., Riisnaes, R., Miranda, S., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.63 · Cited by 65
Liquid Biopsy in Non-Small Cell Lung Cancer
Molina‐Vila, M. Á., Mayo‐de‐las‐Casas, C., Giménez-Capitán, A. A., Jordana‐Ariza, N., Garzón, M., Balada‐Bel, A., Villatoro, S., Teixidó, C., García‐Peláez, B., Aguado, C., et al. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00069 · Cited by 64
Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer
Mao, C., Yuan, J.-Q., Yang, Z., Fu, X., Wu, X., & Tang, J.-L. (2015) · Medicine · doi:10.1097/md.0000000000000775 · Cited by 64
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions
Zhang, Z., Ramnath, N., & Nagrath, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00209 · Cited by 64
Circulating Tumor Cells in Lung Cancer: Detection Methods and Clinical Applications
Yu, N., Zhou, J., Cui, F., & Tang, X. (2015) · Lung · doi:10.1007/s00408-015-9697-7 · Cited by 64
A Fluid Multivalent Magnetic Interface for High‐Performance Isolation and Proteomic Profiling of Tumor‐Derived Extracellular Vesicles
Niu, Q., Shu, Y., Chen, Y., Huang, Z., Yao, Z., Chen, X., Lin, F., Feng, J., Huang, C., Wang, H., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202215337 · Cited by 62
Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer
Nie, K., Jia, Y., & Zhang, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2758-3 · Cited by 61
Is tissue still the issue in detecting molecular alterations in lung cancer?
Liam, C. K., Mallawathantri, S., & Fong, K. M. (2020) · Respirology · doi:10.1111/resp.13823 · Cited by 61
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
Boonstra, P. A., Wind, T. T., van Kruchten, M., Schuuring, E. M. D., Hospers, G. A. P., van der Wekken, A. J., de Groot, D. J. A., Schröder, C. P., Fehrmann, R. S. N., & Reyners, A. K. L. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09876-9 · Cited by 60
Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients
Breitenbuecher, F., Hoffarth, S., Worm, K., Cortes-Incio, D., Gauler, T. C., Köhler, J., Herold, T., Schmid, K. W., Freitag, L., Kasper, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085350 · Cited by 59
Engineered red blood cells for capturing circulating tumor cells with high performance
Zhu, D., Wu, L., Suo, M., Gao, S., Xie, W., Zan, M., Liu, A., Chen, B., Wu, W., Ji, L., et al. (2018) · Nanoscale · doi:10.1039/c7nr08032h · Cited by 57
Self-citation
Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
Agashe, R., & Kurzrock, R. (2020) · Cancers · doi:10.3390/cancers12092361 · Cited by 57
Circulating tumor cells count as a predictor of survival in lung cancer
Syrigos, K., Fiste, O., Charpidou, A. G., & Grapsa, D. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.004 · Cited by 55
Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer
Gallo, M., Luca, A. D., Maiello, M. R., D’Alessio, A., Esposito, C., Chicchinelli, N., Forgione, L., Piccirillo, M. C., Rocco, G., Morabito, A., et al. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.05.07 · Cited by 57
Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
Gao, Y., Song, P., Li, H., Jia, H. M., & Zhang, B. (2017) · BMC Cancer · doi:10.1186/s12885-017-3474-3 · Cited by 55
Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET
Tamminga, M., Andree, K., Hiltermann, T. J. N., Jayat, M., Schuuring, E. M. D., van den Bos, H., Spierings, D. C. J., Lansdorp, P. M., Timens, W., Terstappen, L. W. M. M., et al. (2020) · Cancers · doi:10.3390/cancers12040896 · Cited by 57
What are we learning from the cancer genome?
Collisson, E. A., Cho, R. J., & Gray, J. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.159 · Cited by 55
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
Alama, A., Coco, S., Genova, C., Rossi, G., Fontana, V., Tagliamento, M., Bello, M. G. D., Rosa, A., Boccardo, S., Rijavec, E., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071011 · Cited by 54
Clinical potential of gene mutations in lung cancer
Carper, M. B., & Claudio, P. P. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0074-1 · Cited by 55
Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: 18 F-FDG PET/CT Study
Morbelli, S. D., Alama, A., Ferrarazzo, G., Coco, S., Genova, C., Rijavec, E., Bongioanni, F., Biello, F., Bello, M. G. D., Barletta, G., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193201 · Cited by 52
Recent advances in microfluidic methods in cancer liquid biopsy
Iliescu, F. S., Poenar, D. P., Yu, F., Ni, M., Chan, K. H., Cima, I., Taylor, H. K., Cima, I., & Iliescu, C. (2019) · Biomicrofluidics · doi:10.1063/1.5087690 · Cited by 51
The Role of ctDNA in Gastric Cancer
Mencel, J., Slater, S., Cartwright, E., & Starling, N. (2022) · Cancers · doi:10.3390/cancers14205105 · Cited by 54
The role of molecular imaging in modern drug development
Cunha, L., Szigeti, K., Máthé, D., & Metello, L. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.01.003 · Cited by 51
Early Diagnosis and Screening for Lung CancerPreprint
Kadara, H. N., Tran, L. M., Liu, B., Vachani, A., Li, S., Sinjab, A. F., Zhou, X. J., Dubinett, S. M., & Krysan, K. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037994 · Cited by 51
Developing biomarker-specific end points in lung cancer clinical trials
Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.222 · Cited by 51
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA
Ye, Z., Wang, C., Wan, S., Mu, Z., Zhang, Z., Abu-Khalaf, M. M., Fellin, F., Silver, D. P., Neupane, M., Jaslow, R. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.012 · Cited by 50
Neutrophil membrane-coated immunomagnetic nanoparticles for efficient isolation and analysis of circulating tumor cells
Wu, X., Lin, Z., Zhao, C., Liu, L., Zhang, K., Lai, J., Meng, Q., Yao, G., Huang, Q., Zhao, X., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114425 · Cited by 49
A disposable microfluidic device with a reusable magnetophoretic functional substrate for isolation of circulating tumor cells
Cho, H., Kim, J., Jeon, C.-W., & Han, K.-H. (2017) · Lab on a Chip · doi:10.1039/c7lc00925a · Cited by 49
Pharmacodynamic Biomarkers: Falling Short of the Mark?
Gainor, J. F., Longo, D. L., & Chabner, B. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3132 · Cited by 51
Circulating Biomarkers in Non–Small-Cell Lung Cancer: Current Status and Future Challenges
Matikas, A., Syrigos, K. N., & Agelaki, S. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.021 · Cited by 49
Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer
Yousefi, M., Ghaffari, P., Nosrati, R., Dehghani, S., Salmaninejad, A., Abarghan, Y. J., & Ghaffari, S. H. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00470-y · Cited by 48
Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis
Fan, G., Zhang, K., Ding, J., & Li, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15412 · Cited by 47
An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer
Mayo‐de‐las‐Casas, C., Garzón‐Ibáñez, M., Jordana‐Ariza, N., García‐Peláez, B., Balada‐Bel, A., Villatoro, S., Malapelle, U., Karachaliou, N., Troncone, G., Rosell, R., et al. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1407243 · Cited by 47
Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation
Ulivi, P., Zoli, W., Capelli, L., Chiadini, E., Calistri, D., & Amadori, D. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.100 · Cited by 46
KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer
Kalikaki, A., Politaki, H., Souglakos, J., Apostolaki, S., Papadimitraki, E., Georgoulia, N., Tzardi, M. N., Mavroudis, D., Georgoulias, V., & Voutsina, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104902 · Cited by 46
Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients
Togo, S., Katagiri, N., Namba, Y., Tulafu, M., Nagahama, K. Y., Kadoya, K., Takamochi, K., Oh, S., Suzuki, K., Sakurai, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16818 · Cited by 45
Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs
Chibuk, J., Flory, A., Kruglyak, K. M., Leibman, N. F., Nahama, A., Dharajiya, N. G., van den Boom, D., Jensen, T. J., Friedman, J. S., Shen, M. R., et al. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.664718 · Cited by 45
Aptamer-based nanostructured interfaces for the detection and release of circulating tumor cells
Ding, P., Wang, Z., Wu, Z., Zhu, W., Liu, L., Sun, N., & Pei, R. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02457c · Cited by 44
Biosensors for the Detection of Circulating Tumour Cells
Costa, C., Abal, M., López‐López, R., & Muinelo‐Romay, L. (2014) · Sensors · doi:10.3390/s140304856 · Cited by 43
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43
CTCs 2020: Great Expectations or Unreasonable Dreams
Rossi, E. M. C., & Fabbri, F. (2019) · Cells · doi:10.3390/cells8090989 · Cited by 44
Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors
Castello, A., Carbone, F. G., Rossi, S., Monterisi, S., Federico, D., Toschi, L., & Lopci, E. (2020) · Cancers · doi:10.3390/cancers12020487 · Cited by 43
Cancer–leukocyte hybrid membrane-cloaked magnetic beads for the ultrasensitive isolation, purification, and non-destructive release of circulating tumor cells
Chang, Z., Zhang, R., Yang, C., Shao, D., Tang, Y., Dong, W., & Wang, Z. (2020) · Nanoscale · doi:10.1039/d0nr04097e · Cited by 43
New blood markers detection technology: A leap in the diagnosis of gastric cancer
Beeharry, M. K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1202 · Cited by 42
Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
Watanabe, M., Kenmotsu, H., Ko, R., Wakuda, K., Ono, A., Imai, H., Taira, T., Naito, T., Murakami, H., Abe, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13692 · Cited by 42
Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer
Kapeleris, J., Kulasinghe, A., Warkiani, M. E., O’Leary, C. G., Vela, I., Leo, P., Sternes, P. R., O'Byrne, K. J., & Punyadeera, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-521 · Cited by 43
Analysis of Released Circulating Tumor Cells During Surgery for Non-Small Cell Lung Cancer
Tamminga, M., de Wit, S., Wauwer, C. V. D., van den Bos, H., Swennenhuis, J. F., Klinkenberg, T. J., Hiltermann, T. J. N., Andree, K., Spierings, D. C. J., Lansdorp, P. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2541 · Cited by 41
Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
Woo, H. J., Kim, S., Kang, H. J., Lee, S., Lee, S. J., Kim, J. M., Gurel, O., Kim, S. Y., Roh, H. R., Lee, J., et al. (2022) · Theranostics · doi:10.7150/thno.72511 · Cited by 41
Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer
Ulivi, P., & Silvestrini, R. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0155-3 · Cited by 40
Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma
Salvianti, F., Orlando, C., Massi, D., GIORGI, V. D., Grazzini, M., Pazzagli, M., & Pinzani, P. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00076 · Cited by 39
Recent progress of biosensors for the detection of lung cancer markers
Chen, S., Li, M., Weng, T., Wang, D., & Geng, J. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02277j · Cited by 38
Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC
Nygaard, A. D., Spindler, K. G., Pallisgaard, N., Andersen, R. F., & Jakobsen, A. K. M. (2013) · Oncology Reports · doi:10.3892/or.2013.2906 · Cited by 38
Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer
Alama, A., Truini, A., Coco, S., Genova, C., & Grossi, F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.001 · Cited by 38
Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
Papadaki, M. A., Sotiriou, A., Vasilopoulou, C., Filika, M., Aggouraki, D., Tsoulfas, P. G., Apostolopoulou, C. A., Rounis, K., Mavroudis, D., & Agelaki, S. (2020) · Cancers · doi:10.3390/cancers12061556 · Cited by 38
Liquid biopsy in early stage lung cancer
Pérez-Ramírez, C., Cañadas‐Garre, M., Robles, A. I., Molina‐Vila, M. Á., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.15 · Cited by 39
Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer
Lin, C., Huang, W.-L., Fang, W., Su, W., & Wong, D. T. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1094379 · Cited by 37
Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy
Tamminga, M., de Wit, S., Schuuring, E. M. D., Timens, W., Terstappen, L. W. M. M., Hiltermann, T. J. N., & Groen, H. J. M. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.06 · Cited by 37
Predictive and prognostic value of circulating tumor cell detection in lung cancer: A clinician's perspective
Tognela, A., Spring, K. J., Becker, T. M., Caixeiro, N., Bray, V., Yip, P. Y., Chua, W. M., Lim, S. H.-S., & SOUZA, P. D. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.10.001 · Cited by 36
Circulating Tumor Cells and Circulating Tumor DNA
Lianidou, E. S., & Hoon, D. S. �. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816061-9.00009-6 · Cited by 36
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies
Pawlikowska, P., Faugeroux, V., Oulhen, M., Aberlenc, A., Tayoun, T., Pailler, E., & Farace, F. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.80 · Cited by 37
Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response
Li, R., & Liang, Z.-Y. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001097 · Cited by 39
An Observational Study of Circulating Tumor Cells and 18F-FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer
Nair, V. S., Keu, K. V., Luttgen, M. S., Kolatkar, A. R., Vasanawala, M., Kuschner, W. G., Bethel, K. J., Iagaru, A. H., Hoh, C. K., Shrager, J. B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067733 · Cited by 35
Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer
Wang, H., Zhang, B., Chen, D., Xia, W., Zhang, J., Wang, F., Xu, J., Zhang, Y., Zhang, M., Zhang, L., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0150-9 · Cited by 35
Circulating Tumor Cells and DNA for Real-Time EGFR Detection and Monitoring of Non-Small-Cell Lung Cancer
He, J., Wei, T., & Jing-ping, M. (2017) · Future Oncology · doi:10.2217/fon-2016-0427 · Cited by 36
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
Liang, Z., Cheng, Y., Chen, Y., Hu, Y., Liu, W.-P., Lü, Y., Wang, J., Wang, Y., Wu, G., Ying, J., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.008 · Cited by 36
Self-citation
Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer
Mohan, S., Chemi, F., & Brady, G. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.06.04 · Cited by 36
Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis
Xiao, J., Pohlmann, P. R., Isaacs, C. J., Weinberg, B. A., He, A. R., Schlegel, R., & Agarwal, S. (2021) · Biomedicines · doi:10.3390/biomedicines9091111 · Cited by 36
Biology and clinical significance of circulating tumor cell subpopulations in lung cancer
O′Flaherty, L., Wikman, H., & Pantel, K. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.07.03 · Cited by 36
FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor
Färkkilä, A., McConechy, M. K., Yang, W., Talhouk, A., Ng, Y., Lum, A. M., Morin, R. D., Bushell, K. R., Riska, A., McAlpine, J. N., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.005 · Cited by 34
Highly Selective Capture Surfaces on Medical Wires for Fishing Tumor Cells in Whole Blood
Scherag, F. D., Niestroj-Pahl, R., Krusekopf, S., Lücke, K., Brandstëtter, T., & Rühe, J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04219 · Cited by 34
Efficient isolation and quantification of circulating tumor cells in non-small cell lung cancer patients using peptide-functionalized magnetic nanoparticles
Liang, N., Liu, L., Li, P., Xu, Y., Hou, Y., Peng, J., Song, Y., Bing, Z., Wang, Y., Wang, Y., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1026a · Cited by 33
Non-small-cell lung cancer
Agteresch, H. J., Pieter, C., van der Gaast, A., & Wilson, J. H. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.48 · Cited by 32
Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Low‐Dose Computed Tomography
Kan, C. F. K., Unis, G. D., Li, L. Z., Gunn, S., Li, L., Soyer, H. P., & Stark, M. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.555331 · Cited by 32
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
Ntzifa, A., Kotsakis, A. P., Georgoulias, V., & Lianidou, E. S. (2021) · Cancers · doi:10.3390/cancers13112736 · Cited by 32
Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
Xu, Y., Cai, J., Zhong, K., Wen, Y., Cai, L., He, G., Liao, H., Zhang, C., Fu, S., Chen, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1119744 · Cited by 33
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients
Yang, B., Qin, A., Zhang, K., Ren, H., Liu, S., Liu, X., Pan, X., & Yu, G. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14928634401178 · Cited by 31
Progress and application of circulating tumor cells in non-small cell lung cancer
Qian, H., Zhang, Y., Xu, J., He, J., & Gao, W. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.005 · Cited by 31
A blood cell repelling and tumor cell capturing surface for high-purity enrichment of circulating tumor cells
Li, T., Li, N., Ma, Y., Bai, Y., Xing, C.-M., & Gong, Y. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01649j · Cited by 31
Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer
Hu, W., Yang, Y., Zhang, L., Yin, J., Huang, J., Huang, L., Gu, H., Jiang, G., & Fang, J. (2017) · Cancer Medicine · doi:10.1002/cam4.980 · Cited by 30
Device for whole genome sequencing single circulating tumor cells from whole blood
Li, R., Jia, F., Zhang, W., Shi, F., Fang, Z., Zhao, H. C., Hu, Z., & Wei, Z. (2019) · Lab on a Chip · doi:10.1039/c9lc00473d · Cited by 30
Prognostic value of pre-treatment red blood cell distribution width in lung cancer: a meta-analysis
Wang, Y., Zhou, Y., Zhou, K., Li, J., & Che, G. (2020) · Biomarkers · doi:10.1080/1354750x.2020.1731763 · Cited by 30
18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer
Zhang, F., Wu, X., Zhu, J., Huang, Y., Song, X., & Jiang, L. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05260-z · Cited by 30
Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
Kapeleris, J., Warkiani, M. E., Kulasinghe, A., Vela, I., Kenny, L., Ladwa, R., O'Byrne, K. J., & Punyadeera, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.859152 · Cited by 30
Significance of circulating tumor cells in lung cancer: a narrative review
Hamilton, G., Rath, B., & Stickler, S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-712 · Cited by 30
Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB)
Tu, M. K., Chia, D., Wei, F., & Wong, D. T. (2015) · The Analyst · doi:10.1039/c5an01863c · Cited by 29
Dynamic Changes in Numbers and Properties of Circulating Tumor Cells and Their Potential Applications
Tseng, J.-Y., Yang, C., Liang, S.-C., Liu, R.-S., Jiang, J., & Lin, C.-H. (2014) · Cancers · doi:10.3390/cancers6042369 · Cited by 29
Label-free and high-sensitive detection of Kirsten rat sarcoma viral oncogene homolog and epidermal growth factor receptor mutation using Kelvin probe force microscopy
Jang, K., Choi, J., Park, C., & Na, S. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.08.045 · Cited by 29
Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal
Mentis, A. A., Grivas, P. D., Dardiotis, E., Romas, N. A., & Papavassiliou, A. G. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03529-4 · Cited by 30
EGFR mutations in circulating tumour DNA
Rosell, R., Molina‐Vila, M. Á., & Serrano, M. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70369-8 · Cited by 29
Classifying low-grade and high-grade bladder cancer using label-free serum surface-enhanced Raman spectroscopy and support vector machine
Zhang, Y., Lai, X., Zeng, Q., Li, L., Lin, L., Li, S., Liu, Z., Su, C., Qi, M., & Guo, Z. (2018) · Laser Physics · doi:10.1088/1555-6611/aa9d6d · Cited by 28
Introduction of Nanomaterials to Biosensors for Exosome Detection: Case Study for Cancer Analysis
Lee, M., Kim, J., Jang, M., Park, C., Lee, J., & Lee, T. (2022) · Biosensors · doi:10.3390/bios12080648 · Cited by 28
Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
Andrikou, K., Rossi, T., Verlicchi, A., Priano, I., Cravero, P., Burgio, M. A., Crinò, L., Bandini, S., Ulivi, P., & Delmonte, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216085 · Cited by 30
The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer
Ross, K., Pailler, E., Faugeroux, V., Taylor, M., Oulhen, M., Auger, N., Planchard, D., Soria, J., Lindsay, C. R., Besse, B., et al. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1111139 · Cited by 31
Aptamer-Based Methods for Detection of Circulating Tumor Cells and Their Potential for Personalized Diagnostics
Zamay, A. S., Сергеевна, З. Г., Kolovskaya, O. S., Zamay, T. N., & Berezovski, M. V. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55947-6_3 · Cited by 28
Gradient Magnetic Separation and Fluorescent Imaging‐Based Heterogeneous Circulating Tumor Cell Subpopulations Assay with Biomimetic Multifunctional Nanoprobes
Liao, Z., Han, L., Li, Q., Li, L., Liu, Y., Song, Y., Tan, W., & Song, E. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009937 · Cited by 28

Authors: Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., & Lackner, M. R.
Affiliations: Genentech (US)
ORCID: Punnoose, Elizabeth A.
Liu, Weiqun
Raja, Rajiv
Fine, Bernard M.
Hughes, Brett G.M.
Hicks, Rodney J.
Lackner, Mark R.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-04-15
Volume: 18
Issue: 8
Pages: 2391-2401
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-11-3148
OpenAlex: W2103077070
Cited by: 415
References: 29
Citations by year: 2026: 2 · 2025: 6 · 2024: 14 · 2023: 26 · 2022: 17 · 2021: 27 · 2020: 33 · 2019: 39 · 2018: 34 · 2017: 56 · 2016: 53 · 2015: 38 · 2014: 38 · 2013: 23 · 2012: 8
FWCI: 11.36
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: circulating tumor cells, circulating tumor DNA, non-small cell lung cancer, pertuzumab, erlotinib, EGFR expression, oncogenic mutations, predictive biomarkers, treatment response monitoring, CellSearch, FDG-PET, RECIST, progression-free survival, liquid biopsy
MeSH terms: Erlotinib Hydrochloride, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, DNA, Neoplasm, Female, Genotype, Humans, Lung Neoplasms, Male, Mutation, Neoplastic Cells, Circulating, Quinazolines, Biomarkers, Tumor, Disease-Free Survival, Endpoint Determination, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks